Short hairpin RNA (shRNA) screening identified a transcript that conferred higher susceptibility to sorafenib, a multikinase inhibitor used to treat advanced HCC [51]; additional screening suggested that MPP could be a candidate and that silencing the PMPCB enhanced PINK1 (PTEN-induced putative kinase 1)-Parkin signaling and downregulated the anti-apoptotic protein MCL-1 (induced myeloid leukemia cell differentiation protein 1), thus sensitizing the HCC tumor cells to sorafenib therapy, potentially opening its use for the treatment of liver cancer [52]. The gene discussed is PINK1; the disease is neoplasm.